

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

19th, 20th & 21st December 2025

📍 Hotel Novotel, Andheri East, Mumbai

## SCIENTIFIC AGENDA

HALL-A

Patrons

Dr. S H Advani, Mumbai

Dr. Rajesh Mistry, Mumbai

Dr. V Kannan, Mumbai

### Organizing Secretaries

Dr. Ashay Karpe, Mumbai

Dr. Prashant Chhajed, Mumbai

Dr. Vijay Patil, Mumbai

Dr. Anil Tibdewal, Mumbai

Dr. Priti Eshpuniyan, Mumbai

### Joint Organizing Secretaries

Dr. Nandini Menon, Mumbai

Dr. Akhil Kapoor, Varanasi

### Chair Scientific Committee

Dr. Vanita Noronha, Mumbai

### Scientific Committee

Dr. Kumar Prabhash, Mumbai  
Dr. Trinjan Basu, Mumbai  
Dr. Pratik Chandrani, Mumbai  
Dr. Navneet Singh, Chandigarh

Dr. Ramakant Deshpande, Mumbai  
Dr. Sujith M, Chennai  
Dr. Amit Janu, Mumbai  
Dr. Manoj Mahajan, Udaipur  
Dr. Minit Shah, Mumbai

Dr. Rushabh Kothari, Ahmedabad  
Dr. Anup Toshniwal, Aurangabad  
Dr. Anuradha Chougule, Mumbai  
Dr. Atanu Bhattacharjee, UK

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025



19th, 20th & 21st December 2025

 Hotel Novotel, Andheri East, Mumbai

## Geriatric Oncology Workshop



### CONVENOR

**Dr. Vanita Noronha**

 [vanita.noronha@gmail.com](mailto:vanita.noronha@gmail.com)

 +91 9769328047

 Friday, 19th December 2025

 09:00 - 11:00 AM

 Hall - A

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

**Day 1 : Friday, 19th December 2025 | Time : 09:00 AM - 11:00 AM IST**

TIME	TOPIC / SPEAKER
09:00 - 09:05 AM	Introduction - Geriatric Oncology in India Speaker : Dr. Anupa Pillai, Mumbai
09:05 - 09:20 AM	Loneliness and social isolation in older patients with cancer: Speaker : Dr. Mahati Chittim , Hyderabad
09:20 - 09:35 AM	Chemotherapy related cognitive decline: Associated factors and management Speaker : Dr. Anupa Pillai, Mumbai
09:35 - 10:00 AM	Panel Discussion: Shared decision making in older patients with cancer: implementation and challenges Moderator: Dr. Rejiv Rajendranath, Chennai Panelists: Dr. Tarachand Gupta , Jaipur Dr. Sharada Mailankody , Manipal Dr. NN Prem, Mumbai Dr. Thotup Bhutia, Mumbai Dr. Naeema Nazreen Fatimah,Mumbai Dr. Agnisha Sharma, Mumbai Dr. Sujay Bhandary, Mumbai Dr. Arshiya Sehgal , Mumbai Dr. Priya Singh, Mumbai
10:00 - 10:15 AM	Digital Health with AI in geriatric oncology - new possibilities Speaker : Mr. Ameer Shaikh, Mumbai
10:15 - 10:30 AM	Analgesia in older patients with cancer Speaker : Dr. Thotup Bhutia, Mumbai
10:30 - 10:55 AM	Panel discussion: Management issues in an older patient with cancer Moderator: Dr. Anupa Pillai, Mumbai Panelists: Dr. Anita Kumar , Mumbai Dr. Bharath Pant, Managlore Dr. Renita Catellino , Mumbai Dr. Shreya Gattani, Mumbai Dr. Sarika Mahajan, Mumbai Dr. Lekhika Sonkusare, Mumbai Dr. Purabi Mahajan, Mumbai Ms. S. Raja Venkateswari, Kochi
10:55 - 11:00 AM	Conclusion and vote of thanks Speaker : Dr. Anupa Pillai, Mumbai

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

DAY 1 : 19th December, 2025 | TIME : 11:00 AM - 04:30 PM

## TIME      TOPIC / SPEAKER

11:00 AM Onwards      Welcome & Introduction  
Dr. Prriya Eshpuniyani, Mumbai

Chairperson : Dr. Murad Lala, Mumbai

11:00 AM - 12:00 PM      Surgical Video Session

### Early Stage Lung Cancer

11:00 - 11:10 AM      VATS Lobectomy for early stage lung cancer - video  
Speaker : Dr. Manish Jethani, Mumbai

### Locally Advanced

11:10 - 11:20 AM      VATS Lobectomy post immunotherapy  
Speaker : Dr. Vivek Mundale, Mumbai

11:20 - 11:30 AM      Evolution of HITHOC in intrathoracic malignancies  
Speaker : Dr. Prriya Eshpuniyani, Mumbai

11:30 - 11:40 AM      HITHOC - Video  
Speaker : Dr. Aruna Prabhu, Namakkal

11:40 - 11:50 AM      Malignant pleural effusion - IPC vs ICD. When to do pleurodesis Indian context.  
Literature  
Speaker : Dr. Kanishk Siddhartha, Lucknow

11:50 AM - 12:00 PM      Surgical Options - Oligometastatic - Videos  
Speaker : Dr. Bhushan Thombare, Delhi

### 1. Epidemiology and Screening

12:00 - 12:07 PM      OA01.01 Genetic and Air Pollution Score Identify Individual at Elevated Risk in a  
Lung Cancer Screening Cohort  
Speaker : Dr. Kriti Y C, Mumbai

12:07 - 12:21 PM      Integration of Screening for Lung Cancer in South East Asian Perspective:  
Challenges and Way Forward  
Speaker : Dr. Navneet Singh, Chandigarh




contact@cancerresearchfoundation.in

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

TIME	TOPIC / SPEAKER
2. Early Stage Lung Cancer	
Local Therapy - Surgery and Radiotherapy	
12:21 - 12:28 PM	PL03.13 Survival Outcome of VATS Compared to Open Lobectomy for Lung Cancer: An Individual Patient Data Meta-analysis of Randomized Trial Speaker : Dr. Saravana Rajamanickam, Namakkal
12:28 - 12:35 PM	P1.07.10 Prognostic Impact of Resection Margin Distance in Patients With Completely Resected Stage I NSCLC After Lobectomy Speaker : Dr. Priya Eshpuniyani, Mumbai
12:35 - 12:42 PM	P1.07.24 Radicality of Lymphadenectomy in NSCLC Resection: Impact on Survival. Results From the Spanish Video-Assisted Thoracic Surgery Group (GEVATS) Speaker : Dr. Virendra Tiwari, Mumbai
12:42 - 12:49 PM	P1.07.26 Applicability of Artificial Intelligence Based Tumor Segmentation in Planning for Sublobar Resection in Lung Cancer: A Meta-Analysis Speaker : Dr. Devayani Niyogi, Mumbai
Perioperative/Neoadjuvant /Adjuvant Immunotherapy in Resectable NSCLC	
12:49 - 12:56 PM	PL03.10 Adjuvant Chemotherapy (CT) v CT-immunotherapy for R0 Stage IB-IIIA NSCLC Patient (NADIM ADJUVANT): a Randomized, Phase 3 Trial Speaker : Dr. Bhavesh Poladia, Namakkal
12:56 - 01:03 PM	OA02.03 Overall Survival (OS) with Neoadjuvant Nivolumab Plus Chemotherapy by Surgical Outcome in the Phase 3 CheckMate 816 Study Speaker : Dr. Kapu Venkatesh, Vishakapatnam
01:03 - 01:10 PM	MA01.04 Neoadjuvant PD-(L)1 Blockade in Combination With Chemotherapy for Borderline resectable and unresectable Stage III Non-Small Cell Lung Cancer Speaker : Dr. Kishore Kota, Vizag
01:10 - 01:17 PM	MA01.05 Tisleilizumab Plus Chemotherapy Followed by Surgery or Radiotherapy and Adjuvant Tisleilizumab in Unresectable Stage III NSCLC Speaker : Dr. Lakhan Kashyap, Pune
01:17 - 01:24 PM	Perioperative pembrolizumab in early-stage non-small-cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE-671 Speaker : Dr. Anup Toshniwal, Aurangabad
01:24 - 01:30 PM	NeoADAURA: Neoadjuvant osimertinib in EGFR-mutated early-stage NSCLC. Speaker : Dr. Sudeep Das, Kolkata

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

TIME	TOPIC / SPEAKER
SESSION SPONSORED BY ASTRAZENECA	
01:30 - 01:50 PM	The Emerging Role of Antibody Drug Conjugates in Lung Cancer Speaker : Dr. Vaibhav Chaudhary, Mumbai
01:50 - 02:20 PM	Lunch Break
3. Locally Advanced Non-Small Cell Lung Cancer	
Chairpersons: Dr. Sharmila Agarwal, Mumbai Dr. V Kannan, Mumbai	
Radiotherapy in Locally advanced NSCLC	
02:20 - 02:27 PM	P3.18.17 Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer (NeoRADjuvant) Speaker : Dr. Sanjay MH, Pune
02:27 - 02:34 PM	P3.12.37 First-Line Lazertinib With or Without Local Ablative Radiotherapy in Oligo-Metastatic EGFR- Mutant NSCLC Speaker : Dr. Sumit Basu, Mumbai
02:34 - 02:41 PM	Consolidative Radiotherapy with Osimertinib in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: Long-Term Local and Intracranial Control Results from a Phase II Trial Speaker : Dr. Unmesh Mukherjee, Mumbai
02:41 - 02:48 PM	Ten-Year Outcomes of the Revised STARS Trial Comparing Radiation and Surgery for Early-Stage Non-Small Cell Lung Cancer Speaker : Dr. Tanweer Shahid, Kolkata
02:48 - 02:55 PM	P3.13.27 Toripalimab Consolidation After Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase II, Randomized Controlled Study Speaker : Dr. Prashant Nayak, Mumbai
02:55 - 03:02 PM	Baseline and Time-Dependent Predictors of Cognitive Decline for Brain Metastasis Patients Treated with Radiotherapy- A Secondary Analysis of the ATHENA Trial Speaker : Dr. Pranav Chadda, Mumbai



# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

TIME	TOPIC / SPEAKER
03:02 - 03:30 PM	<p>Panel Discussion: Based on the Above Abstracts</p> <p>Moderator: Dr. Trinanjan Basu, Mumbai</p> <p>Panelists: Dr. Sandeep De, Mumbai Dr. Guncha Maheshwari, Mumbai Dr. Shirley Lewis, Manipal Dr. Chandani Hotwani, Nagpur Dr. Nikhil Kalyani, Mumbai Dr. Saravana Rajamanickam, Namakkal Dr. Sudeep Das, Kolkata Dr. Lakhan Kashyap, Pune</p>
	<p>Chairpersons: Dr. Bhavesh Poladia, Namakkal Dr. Tara Chand Gupta, Jaipur</p>
	<b>4. Advanced Lung Cancer - Driver mutation negative NSCLC</b>
03:30 - 03:37 PM	<p>Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONI-6): a randomised, double-blind, phase 3 trial</p> <p>Speaker : Dr. Manu Prasad, Kannur</p>
03:37 - 03:44 PM	<p>OA05.01 ASTRUM-002: First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Non-squamous Non-Small Cell Lung Cancer</p> <p>Speaker : Dr. Suhas Aagre, Mumbai</p>
03:44 - 03:50 PM	<p>First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap</p> <p>Speaker : Dr. Swarnabindu Banerjee, Kolkata</p>
	<b>5. Oligometastatic NSCLC</b>
03:50 - 03:57 PM	<p>Consolidative Hypofractionated RT for Oligometastatic NSCLC</p> <p>Speaker : Dr. Anil Tibdewal, Mumbai</p>
03:57 - 04:04 PM	<p>Individualized SBRT for Ultra-Central NSCLC Achieves Optimal Tumor Control With Minimal Toxicity</p> <p>Speaker : Dr. Shirley Lewis, Manipal</p>
04:04 - 04:10 PM	<p>Abstract - CURB Trial</p> <p>Speaker : Dr. Sayan Das, Kolkata</p>



# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025



19th, 20th & 21st December 2025

📍 Hotel Novotel, Andheri East, Mumbai

## Cellular Therapy in Cancer (What, When & How)

## Cellular Therapy Workshop

📅 Friday, 19th December 2025

🕒 04:10 - 06:35 PM

📍 Hall - A

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

Day 1 : Friday, 19th December 2025 | Time : 04:10 AM - 06:35 AM IST

TIME	TOPIC	FACULTY
04:10 - 04:20 PM	TIL Therapy in Melanoma Speaker : Dr. Manoj Mahajan, Udaipur	
04:20 - 04:25 PM	TIL Therapy in Cervical Cancer Speaker : Dr. Manoj Mahajan, Udaipur	
04:25 - 04:55 PM	TIL Panel Discussion Moderator: Dr. Nandini Menon, Mumbai Panelists: Dr. S H Advani, Mumbai Dr. Akhil Kapoor, Varanasi Dr. Jyoti Bajpai, Mumbai Dr. Vijay Patil, Mumbai Dr. Manu Prasad, Kannur Dr. Avinash Talele, Mumbai Dr. Kiran Kumar Matta, Nashik	
04:55 - 05:05 PM	CAR-T in Gastric cancers Speaker : Dr. Gautam Goyal, Mohali	
05:05 - 05:15 PM	CAR-T in Glioblastoma Speaker : Dr. Kritika Mehrotra, Mumbai	
05:15 - 05:25 PM	CAR-T in Midline Glioma Speaker : Dr. Amit Jain, Mumbai	
05:25- 05:35 PM	CAR-T in Neuroblastoma Speaker : Dr. Sneha Shinde, Mumbai	
05:35 - 05:45 PM	New Proven Data in CART Speaker : Dr. Prerna, Mumbai	
05:45 - 06:15 PM	CAR-T Panel Discussion Moderator: Dr. Vijay Patil, Mumbai Panelists: Dr. Prabhat Bhargava, Mumbai Dr. Nandini Menon, Mumbai Dr. Vaibhav Chaudhary, Mumbai Dr. Pritam Kataria, Mumbai Dr. Madhura Agre, Mumbai Dr. Pawan Singh, Ahmedabad	
06:15 - 06:25 PM	TCR-T in Synovial Sarcoma Speaker : Dr. Ashay Karpe, Mumbai	
06:25 - 06:35 PM	TCR-T in other solid tumours Speaker : Dr. Simit Sapkota, Nepal	
06:35 PM Onwards	Closing Remarks Followed By Dinner	

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

DAY 2 : 20th December, 2025 | TIME : 09:00 AM - 08:30 PM

TIME	TOPIC / SPEAKER
09:00 AM Onwards	Welcome & Introduction Dr. Ashay Karpe, Mumbai
	Chairpersons: Dr. Roshni Pande, Jabalpur Dr. Suman Mittal, Raipur
6. Advanced Lung Cancer - EGFR Mutation Positive	
First Line EGFR	
09:00 - 09:07 AM	PL02.09 Aumolertinib plus Chemotherapy for NSCLC with EGFR and Concomitant Tumor Suppressor Gene (ACROSS 2): Phase III study Speaker : Dr. Mansi Sharma, Delhi
09:07 - 09:14 AM	FLAURA2: Exploratory OS analysis—osimertinib + platinum-pemetrexed in poorer-prognosis EGFR-mutant NSCLC Speaker : Dr. Soumya Surath Panda, Bhubaneswar
09:14 - 09:21 AM	Beamion LUNG-1 (Phase Ib): Zongertinib first-line in HER2-mutant NSCLC Speaker : Dr. Satish Sharma, Ranchi
09:21 - 09:28 AM	Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase 2 trial Speaker : Dr. Prahad Elamarthi, Bangalore
09:28 - 09:35 AM	Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. Speaker : Dr. Jayant Gawande, Pune
09:35 - 09:42 AM	NeoADAURA: Neoadjuvant osimertinib in EGFR-mutated early-stage NSCLC. Speaker : Dr. Ramavath Dev, Vizag
Second line and beyond in EGFR mutated NSCLC & emerging data	
09:42 - 09:49 AM	OptiTROP-Lung04 (Phase III): Sacituzumab tirumotecan (TROP2-ADC) vs platinum chemo after EGFR-TKI Speaker : Dr. Lakshmi Sandhya S, Tirupati



contact@cancerresearchfoundation.in

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

## TIME      TOPIC / SPEAKER

09:49 - 09:56 AM	Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study Speaker : Dr. Aditya Dhanawat, Mumbai
09:56 - 10:03 AM	Second-line therapy following osimertinib in metastatic EGFR-mutated non-small cell lung cancer at an academic medical center Speaker : Dr. Shikhar Kumar, Hyderabad
10:03 - 10:10 AM	Genomic Profiling of Driver Gene Alterations in Patients With Non-Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 Patients Speaker : Dr. Simit Sapkota, Nepal
10:10 - 10:40 AM	Panel Discussion: EGFR mutated lung cancer (both sessions) Moderator: Dr. Ashish Singh, Vellore Panelists: Dr. Priya Tiwari, Delhi Dr. M V Chandrakanth, Kolkata Dr. Dilip Harindran Vallathol, Kochi Dr. Sunil Chopade, Mumbai Dr. Soumya Surath Panda, Bhubaneswar Dr. Aparna Dhar, Delhi Dr. Aditi Thanky, Rajkot Dr. Ramavath Dev, Vizag

## SESSION SPONSORED BY MSD

10:40 - 11:00 AM	Treatment Evolution of Non-squamous Non-small Cell Lung Cancer Speaker : Dr. Aditi Thanky, Rajkot
------------------	--

## SESSION SPONSORED BY ASTRAZENECA

11:00 - 11:30 AM	Panel Discussion: Redefining First-Line and Sequencing Strategies in Advanced EGFRm NSCLC Moderator: Dr. Ullas Batra, Delhi Panelists: Dr. M V Chandrakanth, Kolkata Dr. Shailesh Bondarode, Nashik Dr. Amit Kumar, Patna Dr. Akhil Kapoor, Varanasi
------------------	---



[contact@cancerresearchfoundation.in](mailto:contact@cancerresearchfoundation.in)

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

TIME	TOPIC / SPEAKER
SESSION SPONSORED BY ROCHE	
11:30 AM - 12:00 PM	Personalizing Immunotherapy in mNSCLC; Tecentriq evidence journey Moderator: Dr Sewanti Limaye , Mumbai Panelists: Dr Navneet Singh , Chandigarh Dr Tarachand Gupta , Jaipur Dr Nitin Yahas , Bangalore Dr Minit Shah , Mumbai Dr. Priya Tiwari, Delhi
CRSF Oration & Felicitation	
	Chairpersons: Dr. S H Advani, Mumbai Dr. B K Mishra, Varanasi
12:00 - 12:45 PM	Regulation of Clinical Trials in India: Special Relevance to Oncology Trial and future direction Speaker : Prof. (Dr.) Bikash Medhi, Chandigarh
12:45 - 01:00 PM	Lung Connect & Felicitation
12:45 - 12:55 PM	Talk About Lung Connect
12:55 - 01:00 PM	Felicitation (2 Patient, 1 Caregiver and 2 Navigator) & Ravi Prakash Memorial Awards
01:00 - 01:30 PM	Lunch Break
	Chairpersons: Dr. B K Mishra, Varanasi Dr. Sandeep Jasuja, Jaipur
7. Advanced Lung Cancer - ALK and ctDNA	
01:30 - 01:37 PM	PL02.18 Phase 3 Trial of Crizotinib vs Observation for Surgically Resected Early-Stage ALK+ NSCLC Speaker : Dr. Syed Nisar, Srinagar
01:37 - 01:44 PM	Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study Speaker : Dr. Darshit Shah, Mumbai
01:44 - 01:51 PM	A Decade of Treating ALK-Rearranged Non-Small Cell Lung Cancer in a Lower Middle-Income Country: Changing Patterns and Improving Survival Speaker : Dr. Deep Vora, Mumbai



[contact@cancerresearchfoundation.in](mailto:contact@cancerresearchfoundation.in)

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

TIME	TOPIC / SPEAKER
01:51 - 01:58 PM	Final overall survival (OS) and safety analysis of the Phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC) Speaker : Dr. Arun Chandrasekhar, Calicut
01:58 - 02:05 PM	Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non-Small Cell Lung Cancer: An Updated Meta-Analysis Speaker : Dr. Gaurav Kumar, Muzaffarpur
02:05 - 02:30 PM	Panel Discussion: Based on the Above Topics Moderator: Dr. Ullas Batra, Delhi Panelists: Dr. Arun Chandrasekhar, Calicut Dr. Shailesh Bondarde, Nashik Dr. Darshit Shah, Mumbai Dr. Sunil Pasricha, Delhi Dr. Minit Shah, Mumbai Dr. Kshitij Domadia, Ahmedabad Dr. Deep Vora, Mumbai Dr. Manu Prasad, Kannur Dr. Mubarakunnisa Tonse, Mumbai
SESSION SPONSORED BY TAKEDA	
02:30 - 02:50 PM	ALT Strategies in the Management of ALK+ NSCLC with ALUNBRIG Speaker : Dr. Akhil Kapoor, Varanasi
SESSION SPONSORED BY PFIZER	
02:50 - 03:30 PM	The ALK Odyssey: Tracing the path from diagnosis to innovation Moderator: Dr. S H Advani, Mumbai Panelists: Dr. Minit Shah, Mumbai Dr. M V Chandrakanth, Kolkata Dr Vinayak Makka , Bengaluru Dr. Kshitij Domadia, Ahmedabad
SESSION SPONSORED BY INTAS	
03:30 - 03:50 PM	Panel Discussion: Re-inventing the wheel in NSCLC with Serplulimab: Updates from WCLC and ESMO 2025 Moderator: Dr. Ullas Batra, Delhi Panelists: Dr. Akhil Kapoor, Varanasi Dr. Ashish Singh , Vellore Dr. Ravi Jaiswal, Raipur Dr. Kshitij Domadia, Ahmedabad Dr. M V Chandrakanth, Kolkata

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

TIME	TOPIC / SPEAKER
SESSION SPONSORED BY BMS	
03:50 - 04:30 PM	<p>Breaking Frontiers in 1L mNSCLC Leveraging Anti PD-1 &amp; Anti CTLA-4 for high unmet need patients</p> <p><b>Moderator:</b> Dr. S H Advani, Mumbai</p> <p><b>Panelists:</b> Dr. Ravi Jaiswal, Raipur Dr. Akash Tiwari, Indore Dr. M V Chandrakanth, Kolkata Dr. Shivam Shingla, Mumbai</p>
Chairperson: Dr S H Advani , Mumbai	
SESSION SPONSORED BY ROCHE	
04:30 - 05:00 PM	<p>Lighting new hope in ES-SCLC with 6 year reported overall survival</p> <p><b>Moderator:</b> Dr. T P Sahoo, Bhopal</p> <p><b>Panelists:</b> Dr. Akash Tiwari, Indore Dr. Arun Chandrasekhar, Calicut Dr. M V Chandrakanth, Kolkata Dr Arvind Vaidyanathan , Mumbai</p>
Chairpersons: Dr. Birendra Kumar Yadav, Nepal Dr. Simit Sapkota, Nepal	
8. ROS-1/BRAF/MET/KRAS/HER-2 and other rare drivers	
05:00 - 05:07 PM	<p>18P: Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing nonsquamous EGFR wildtype advanced NSCLC: Updated analysis of the LUMINOSITY trial</p> <p><b>Speaker :</b> Dr. Kunal Jobanputra, Mumbai</p>
05:07 - 05:14 PM	<p>Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: update from the LOXO-RAS-20001 trial</p> <p><b>Speaker :</b> Dr. Ajay Singh, Lucknow</p>
05:14 - 05:21 PM	<p>Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy</p> <p><b>Speaker :</b> Dr. Abhinav Zawar, Aurangabad</p>
05:21 - 05:28 PM	<p>Sevabertinib (BAY 2927088) in advanced HER2-mutant NSCLC — SOHO-01 study</p> <p><b>Speaker :</b> Dr. Deepak Koppaka, Hyderabad</p>
05:28 - 05:35 PM	<p>ARROS-1 Trial - Zidesamtinib in Advanced ROS1+ NSCLC (WCLC 2025)</p> <p><b>Speaker :</b> Dr. Siddharth Turkar, Mumbai</p>

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

TIME	TOPIC / SPEAKER
05:35 - 06:00 PM	<p>Panel Discussion: Based on the Above Topics</p> <p><b>Moderator:</b> Dr. T P Sahoo, Bhopal</p> <p><b>Panelists:</b></p> <ul style="list-style-type: none"><li>Dr. Anuradha Chougule, Mumbai</li><li>Dr. Deepak Koppaka, Hyderabad</li><li>Dr. Parmod Kumar Pal, Jodhpur</li><li>Dr. Pushpak Chirmade, Mumbai</li><li>Dr. Birendra Kumar Yadav, Nepal</li><li>Dr. Madala Ravikrishna, Hyderabad</li><li>Dr. Nagesh Shirsath, Pune</li><li>Dr. Annu Rajpurohit, Jodhpur</li><li>Dr Akanksha Chaudhary ,Bhopal</li></ul>
<b>SESSION SPONSORED BY MSD</b>	
06:00 - 06:20 PM	<p>Moving the needle for mNSCLC management – focusing on PD-L1 negatives -</p> <p><b>Speaker :</b> Dr. Shivam Shingla, Mumbai</p>
<b>SESSION SPONSORED BY JOHNSON &amp; JOHNSON</b>	
06:20 - 06:35 PM	<p>Role of amivantamab in the EGFRm NSCLC</p> <p><b>Speaker :</b> Dr. Ashish Singh, Vellore</p>
<b>SESSION SPONSORED BY JOHNSON &amp; JOHNSON</b>	
06:35 - 07:05 PM	<p>Panel Discussion: From progression to possibilities: transforming management of EGFRm NSCLC</p> <p><b>Moderator:</b> Dr. Vaibhav Choudhary, Mumbai</p> <p><b>Panelists:</b></p> <ul style="list-style-type: none"><li>Dr. Ashish Singh, Vellore</li><li>Dr. Darshit Shah, Mumbai</li><li>Dr. M V Chandrakanth, Kolkata</li><li>Dr. Jyoti Bajpai, Mumbai</li><li>Dr. Kshitij Domadia, Ahmedabad</li><li>Dr. Vijay Patil, Mumbai</li></ul>
<b>SESSION SPONSORED BY ASTRAZENECA</b>	
07:05 - 07:35 PM	<p>Panel Discussion: Transforming the Unresectable Stage III NSCLC Landscape: From PACIFIC to LAURA</p> <p><b>Moderator:</b> Dr. Akhil Kapoor, Varanasi</p> <p><b>Panelists:</b></p> <ul style="list-style-type: none"><li>Dr. Srikanth Tiwari, Bhopal</li><li>Dr. Bhooshan Zade, Pune</li><li>Dr. Prasanth Penumadu, Tirupati</li><li>Dr. Parmod Kumar Pal, Jodhpur</li><li>Dr. Rohit Malde, Mumbai</li><li>Dr. Karthik V, Mumbai</li></ul>

Speaker : Dr. Gaurav Kumar, Muzaffarpur

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

TIME	TOPIC / SPEAKER
SESSION SPONSORED BY DR. REDDY'S	
07:35 - 07:55 PM	Evolving Trends of NewerI/O in management of Cancer in India Speaker : Dr. Pushpak Chirmade, Mumbai
SESSION SPONSORED BY ELI LILLY	
07:55 - 08:25 PM	RET-Driven Cancers: Evolving Paradigms in precision oncology Speaker : Dr. Akhil Kapoor, Varanasi
08:25 PM Onwards	Closing Remarks Followed By Dinner



# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

DAY 3 : 21st December, 2025 | TIME : 08:00 AM - 01:00 PM

TIME	TOPIC / SPEAKER
08:00 - 09:00 AM	Quiz for Students Quiz Masters: Dr. Kunal Jobanputra, Mumbai Dr. Nitin Yashas, Bangalore
09:00 AM Onwards	Welcome & Introduction Dr. Ashay Karpe, Mumbai
	Chairpersons: Dr. Gautam Goyal, Mohali Dr. Srikant Tiwari, Bhopal Dr. Mohit Sharma, Delhi
9. SCLC	
09:00 - 09:07 AM	IMforte: Maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer (SCLC) vs atezolizumab alone. Speaker : Dr. Sunil Chopade, Mumbai
09:07 - 09:14 AM	DeLLphi-304: Phase 3 of tarlatamab vs chemotherapy for SCLC after progression on platinum-based therapy. Speaker : Dr. Suparna Rao, Mumbai
09:14 - 09:21 AM	DeLLphi-303: Tarlatamab with first-line chemo-immunotherapy for ES-SCLC. Speaker : Dr. Chakor Vora, Pune
09:21 - 09:28 AM	Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage SCLC — Primary Analysis of Phase 2 IDeate-Lung01 (Oral Abstract OA06.03) Speaker : Dr. Anura Kantak, Goa
09:28 - 09:35 AM	Distinct Clinical and Biological Features of Five SCLC Subtypes Identified by Plasma Proteomic Analysis Speaker : Dr. Trupti Pai, Mumbai
09:35 - 10:00 AM	Panel Discussion: Based on the Above Topics Moderator: Dr. Prabhat Malik, Delhi Panelists: Dr. Anura Kantak, Goa Dr. Goli Vasu Babu, Hyderabad Dr. Divya Khosla, Chandigarh Dr. Manoj Mahajan, Udaipur Dr. Nandini Menon, Mumbai Dr. Sanjay Agarwal, Mumbai Dr. Abhishek Sharma, Jodhpur Dr. Yashwant Kashyap, Raipur

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025


TIME	TOPIC / SPEAKER
SESSION SPONSORED BY ASTRAZENECA	
10:00 - 10:20 AM	Transforming the SCLC Treatment Paradigm with Durvalumab Speaker : Dr. Vijay Patil, Mumbai
SESSION SPONSORED BY MSD	
10:20 - 10:40 AM	Non-Squamous mNSCLC the way forward The Breakthrough of Immunotherapy Speaker : Dr. Pritam Kataria, Mumbai
SESSION SPONSORED BY ROCHE	
10:40 - 11:10 AM	Panel Discussion: Optimizing ALK TKI Selection for Holistic Management of ALK+ mNSCLC Moderator: Dr. Akhil Kapoor, Varanasi Panelists: Dr. Chakor Vora, Pune Dr. Manoj Mahajan, Udaipur Dr. Arvind Vaidyanathan, Mumbai Dr. Shivam Shingla, Mumbai
SESSION SPONSORED BY GLENMARK	
11:10 - 11:30 AM	Immuno-Oncology in Motion: Tislelizumab Promise for Lung Carcinoma Speaker : Dr. Vaibhav Choudhary, Mumbai
SESSION SPONSORED BY MSD	
11:30 - 11:50 AM	Treatment Evolution of Squamous Non-small Cell Lung Cancer Speaker : Dr. Jeyhan B Dhabhar, Mumbai
Chairperson : Dr. Maheboob Basade, Mumbai	
10. Supportive Care - Abstracts	
11:50 - 11:57 AM	Unmet supportive care needs in patients with advanced cancer and its impact on distress Speaker : Dr. Sandeep Ishi, Nashik
11:57 AM - 12:04 PM	Comparative effectiveness of pharmacological and non-pharmacological interventions for dyspnea management in advanced cancer: A systematic review and network meta-analysis Speaker : Dr. Karan Sood, Mumbai

# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025

TIME	TOPIC / SPEAKER
12:04 - 12:11 PM	Pilot Feasibility Trial of a Supportive Care Digital Application for Patients with Advanced Non-Small Cell Lung Cancer Speaker : Dr. Akansha Choudhary, Bhopal
12:11 - 12:18 PM	Frailty in motion: How Fitbit data reflects patients with cancers' functional status in the All-of-Us database Speaker : Dr. Mounika Boppana, Hyderabad
12:18 - 12:40 PM	Panel Discussion: Based on the Above Topics Moderator: Dr. Amit Kumar, Patna Panelists: Dr. Vijay Patil, Mumbai Dr. Prabhat Malik, Delhi Dr. Alok Goel, Chandigarh Dr. Sandeep Ishi, Nashik Dr. Minit Shah, Mumbai Dr. Mounika Boppana, Hyderabad Dr. Mohit Sharma, Delhi Dr. Akansha Choudhary, Bhopal
12:40 PM Onwards	Valedictory Function Followed By Lunch



# 9<sup>th</sup> Annual Year End Review In Lung Cancer 2025



## ACADEMIC PARTNERS



**MSD**



Johnson&Johnson  
Innovative Medicine



Bristol Myers Squibb™



Dedicated To Life

